|Bid||0.00 x 39400|
|Ask||0.00 x 1100|
|Day's Range||43.23 - 43.39|
|52 Week Range||41.57 - 47.89|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.07%|
The disconnect between U.S. equities and international stocks is growing wider, but this disparity will not last forever. After the recent underperformance in foreign markets, exchange traded fund investors may find an opportune moment to jump into relatively cheap global equities. For instance, if one looks at price momentum – it is positive for US stocks and negative for Europe and Emerging markets across all relevant lookback windows [one month, three months, six months and 12 months].
Stocks across the globe have suffered their worst first half in a year since 2010, wiping out trillions of dollars from the MSCI's 47-country world index. Inside the hot and flop ETFs in terms of fund flows.
VALLEY FORGE, Pa., July 2, 2018 /PRNewswire/ -- Vanguard today announced substantial reductions in the cost of investing with the firm by providing commission-free online transactions for the vast majority of ETFs. Vanguard, which has offered commission-free transactions of Vanguard ETFs since 2010, is broadening access beyond the company's 77 low-cost ETFs to nearly 1,800 offerings, including ETFs from BlackRock, Schwab, and SSgA. "Vanguard has led the industry in reducing the cost and complexity of investing for all investors for more than four decades.
E*TRADE Financial Corporation today announced it has surpassed 250 commission-free ETFs with the addition of 46 ETFs from six providers to its Commission-Free ETF Pr
GlaxoSmithKline (GSK) reported EPS of 24.60 British pence on revenue of 7.22 billion pounds, surpassing Wall Street analysts’ consensus estimates of 24.21 pence on revenue of 7.20 billion pounds, in Q1 2018.
AstraZeneca (AZN) is one of the leading pharmaceutical companies that deals with primary care and specialty care products. Though it’s headquartered in London, England, the company reports its revenue in US dollars. The company is set to release its 1Q18 earnings on May 18.
GlaxoSmithKline’s (GSK) Pharmaceuticals business includes various Immuno-inflammation products, HIV products, Respiratory products, and Established products. The Pharmaceuticals business segment reported revenues of ~4.0 billion pounds in 1Q18.
Some new exchange-traded funds are well-timed. Others, not so much. To be fair, good timing with new ETFs is often a matter of coincidence, but as the old saying goes, “it's better to be lucky than good.” ...
One of the more notable themes in the world of exchange-traded funds last year was investors affinity for international equity funds. When 2017 drew to a close, five of the year's top 10 asset-gathering ...
The excitement surrounding the tournament and its impact on the stock world has led investors to look at ETFs that could act as a proxy for the game.
GlaxoSmithKline (GSK) estimates that almost 65% of the global multiple myeloma (or MM) drug sales are realized in the US. The demand in the MM segment is mainly driven by the aging population, which has resulted in rising annual incidence by around 2% for the disease. Currently, Johnson & Johnson’s (JNJ) anti-CD38 monoclonal antibody, Darzalex (daratumumb) is witnessing rapid uptake in the MM segment due to its higher efficacy as compared to the previous standard of care therapy.
On November 21, 2017, the U.S. Food and Drug Administration (or FDA) approved Jucala, a two-drug oral regimen comprising of dolutegravir and rilpivirine for patients suffering with HIV-1 infections who have not demonstrated treatment failure or history of drug resistance to the individual components of the new therapy. Juluca is commercialized by ViiV Healthcare, a joint venture of GlaxoSmithKline (GSK), Pfizer (PFE), and Shinogi. Since the current standard of care includes three or more drugs, the two drug regimen could help reduce toxicity levels for treated patients.
GlaxoSmithKline (GSK) is a leading player in the global respiratory market with a major focus on the asthma and chronic obstructive pulmonary disease (or COPD) segments. The company has estimated global asthma prevalence to be around 250 million with 40% of the treated patients continuing to witness symptoms that affect the quality of their lives. To capitalize on this unmet demand, GlaxoSmithKline aims to deliver the right inhaled corticosteroid (or ICS) or combination regimen to the right patients and to ensure proper drug adherence.